Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | RHOC | P08134 | 2/20 | 0.41 |
| ▸ | RHOA | P61586 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599514 | 0.88 | TACR1 (0.54) | TACR1GPBAR1MTORRHOCRHOA | |
| SCHEMBL27312583 | 0.79 | LMNA (0.53) | TACR1GPBAR1MTORRHOCRHOA | |
| SCHEMBL3559178 | 0.79 | PIN1 (0.45) | TACR1GPBAR1HTR2A | |
| SCHEMBL5084706 | 0.77 | TACR1 (0.59) | TACR1GPBAR1MTORRHOCRHOA | |
| SCHEMBL1921828 | 0.75 | TACR1 (0.49) | TACR1GPBAR1 | |
| SCHEMBL1600175 | 0.74 | TACR1 (0.46) | TACR1GPBAR1MTORRHOCRHOA | |
| SCHEMBL14629998 | 0.73 | MPO (0.39) | HTR2A | |
| SCHEMBL27312392 | 0.72 | TACR1 (0.60) | TACR1GPBAR1 | |
| SCHEMBL3556844 | 0.71 | CETP (0.48) | TACR1GPBAR1 | |
| SCHEMBL27312602 | 0.71 | TACR1 (0.67) | TACR1GPBAR1MTORRHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1737811-A4 | CETP INHIBITORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | TACR1 3645/4885GPBAR1 286/4885MTOR 2466/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | TACR1 3645/4885GPBAR1 286/4885MTOR 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.